A A Miller

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. pmc Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    BMC Cancer 12:404. 2012
  2. ncbi request reprint Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd, Winston Salem, NC 27157, USA
    Lung Cancer 48:399-407. 2005
  3. ncbi request reprint Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer
    Antonius A Miller
    Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
    J Thorac Oncol 1:832-6. 2006
  4. ncbi request reprint Phase I study of lenalidomide in solid tumors
    Antonius A Miller
    Wake Forest University, Comprehensive Cancer Center, Winston Salem, NC 27157, USA
    J Thorac Oncol 2:445-9. 2007
  5. ncbi request reprint Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763
    Antonius A Miller
    Wake Forest University, Winston Salem, North Carolina 27157, USA
    Clin Cancer Res 10:8325-31. 2004
  6. ncbi request reprint Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002
    Antonius A Miller
    Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
    J Thorac Oncol 2:645-51. 2007
  7. ncbi request reprint Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
    Antonius A Miller
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
    J Clin Oncol 25:3055-60. 2007
  8. doi request reprint Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)
    Antonius A Miller
    Wake Forest University, Winston Salem, North Carolina, USA
    J Thorac Oncol 3:1159-65. 2008
  9. pmc Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Wake Forest University School of Medicine, Winston Salem, NC, USA
    J Clin Oncol 27:1800-5. 2009
  10. pmc A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd, WinstonSalem, NC 27157, USA
    J Thorac Oncol 5:380-4. 2010

Detail Information

Publications36

  1. pmc Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    BMC Cancer 12:404. 2012
    ..The current study examines Ang-(1-7) induced changes in biomarkers according to cancer type and investigates mechanisms of action engaged in vitro...
  2. ncbi request reprint Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd, Winston Salem, NC 27157, USA
    Lung Cancer 48:399-407. 2005
    ..This Phase II trial was designed to determine the response rate, survival, failure-free survival, and toxicity of second-line therapy with karenitecin in patients with relapsed or refractory non-small cell lung cancer (NSCLC)...
  3. ncbi request reprint Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer
    Antonius A Miller
    Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
    J Thorac Oncol 1:832-6. 2006
    ..We hypothesized that thalidomide would improve the response and toxicity profile of chemotherapy with carboplatin and irinotecan...
  4. ncbi request reprint Phase I study of lenalidomide in solid tumors
    Antonius A Miller
    Wake Forest University, Comprehensive Cancer Center, Winston Salem, NC 27157, USA
    J Thorac Oncol 2:445-9. 2007
    ..The secondary objective was to document any antitumor activity...
  5. ncbi request reprint Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763
    Antonius A Miller
    Wake Forest University, Winston Salem, North Carolina 27157, USA
    Clin Cancer Res 10:8325-31. 2004
    ..v. over 3 hours to female patients, and to evaluate prospectively the relationships between the following: body surface area and toxicity; body surface area and pharmacokinetics; and pharmacokinetics and toxicity...
  6. ncbi request reprint Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002
    Antonius A Miller
    Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
    J Thorac Oncol 2:645-51. 2007
    ....
  7. ncbi request reprint Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
    Antonius A Miller
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
    J Clin Oncol 25:3055-60. 2007
    ..We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction...
  8. doi request reprint Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)
    Antonius A Miller
    Wake Forest University, Winston Salem, North Carolina, USA
    J Thorac Oncol 3:1159-65. 2008
    ..We investigated dose-dense docetaxel and cisplatin in patients with measurable non-small cell lung cancer in a randomized phase II study without [A] or with [B] a putative chemoprotective agent, BNP7787...
  9. pmc Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Wake Forest University School of Medicine, Winston Salem, NC, USA
    J Clin Oncol 27:1800-5. 2009
    ..We sought to characterize the pharmacokinetics (PK) and determine a tolerable dose of oral sorafenib in patients with hepatic or renal dysfunction...
  10. pmc A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd, WinstonSalem, NC 27157, USA
    J Thorac Oncol 5:380-4. 2010
    ..The primary objective of this study was to determine the efficacy of second-line dasatinib in patients with chemosensitive (relapse or progression > or =90 days after completing first-line therapy) small cell lung cancer...
  11. ncbi request reprint Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide
    A A Miller
    Veterans Affairs Medical Center Memphis, 1030 Jefferson Avenue, Memphis, TN 38104, USA
    Lung Cancer 33:241-8. 2001
    ..73 to 1.69 ng/ml, and mean etoposide concentrations ranged from 60 to 230 ng/ml. This sequence of topotecan, carboplatin, and etoposide appeared tolerable and active. Neutropenia was the dose-limiting toxicity...
  12. ncbi request reprint Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 54:379-85. 2006
    ..In conclusion, neutropenia and thrombocytopenia were dose-limiting. The maximum tolerated dose (MTD) is topotecan 3mg/day p.o. days 1-5, carboplatin AUC 5i.v. day 6, and etoposide 150 mg/day p.o. days 6-10 with filgrastim...
  13. ncbi request reprint Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062)
    A A Miller
    University of Tennessee, Memphis, Tennessee 38163, USA
    Clin Cancer Res 3:719-25. 1997
    ..001). Neither EC nor Efree showed a significant correlation with tumor response. A pharmacokinetic relationship between EC or Efree and age was found. A pharmacodynamic model could be developed for toxicity but not for tumor response...
  14. doi request reprint A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer
    Brian Center
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27516, USA
    J Thorac Oncol 5:69-74. 2010
    ..This study sought to define the maximum tolerated dose of weekly docetaxel that could be given with daily gefitinib and concurrent thoracic radiation therapy...
  15. ncbi request reprint Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732
    Harvey B Niell
    University of Tennessee, Memphis, TN 31187, USA
    J Clin Oncol 23:3752-9. 2005
    ....
  16. ncbi request reprint Small cell lung cancer: have we made any progress over the last 25 years?
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
    Oncologist 12:1096-104. 2007
    ..It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve...
  17. ncbi request reprint A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    J Thorac Oncol 2:197-202. 2007
    ..This phase II clinical trial was performed using a non-platinum-based chemotherapy doublet. The impact of previously identified polymorphisms on clinical outcomes was assessed...
  18. doi request reprint Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
    Lynsay L Waller
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, NC, USA
    Lung Cancer 67:12-6. 2010
    ..Individually, the selection and dosing of erlotinib for the treatment of lung cancer patients who continue to smoke is a clinical challenge...
  19. ncbi request reprint The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033
    M J Naughton
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
    Qual Life Res 11:235-48. 2002
    ..Brain involvement, being male, and higher depressive symptoms were also found to be borderline significant in predicting decreased survival in this patient population...
  20. ncbi request reprint Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Clin Oncol 24:407-12. 2006
    ..We investigated whether the disparity in survival would persist when patients were treated with similar therapies (ie, phase II/III Cancer and Leukemia Group B [CALGB] trials)...
  21. pmc Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    Clin Cancer Res 15:7398-404. 2009
    ..Secondary objectives were to assess toxicities, pharmacokinetics, clinical activity, and plasma biomarkers...
  22. ncbi request reprint Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study
    Robert Chin
    Department of Medicine, Section of Pulmonary and Critical Care, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1054, USA
    Lung Cancer 37:1-6. 2002
    ..Whether FDG-PET will replace other more established staging modalities remains to be determined by larger prospective randomized controlled studies...
  23. ncbi request reprint Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston Salem, North Carolina 27516, USA
    J Thorac Oncol 1:434-40. 2006
    ..The safety of dose-escalated thoracic radiation concurrent with gemcitabine in patients with inoperable stage III non-small cell lung cancer has not been studied...
  24. ncbi request reprint Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy
    Peter E Clark
    Department of Urology and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    Urology 67:1257-61. 2006
    ..To report a prospective trial of lycopene supplementation in biochemically relapsed prostate cancer...
  25. ncbi request reprint Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Clin Lung Cancer 6:287-92. 2005
    ..Interdigitating split-course thoracic RT delivered in 2.5-Gy fractions was tolerable in patients with limited-stage SCLC but did not provide a survival advantage...
  26. ncbi request reprint The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, NC 27157 1030, USA
    Cancer 110:911-7. 2007
    ..This study was designed to investigate whether the mortality from heart disease, a manifestation of intercurrent disease after postoperative radiotherapy (PORT), has decreased over time for patients with nonsmall cell lung cancer (NSCLC)...
  27. doi request reprint Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Wake Forest University Health Sciences, Department of Radiation Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 64:226-31. 2009
    ..In order to continue to improve clinical outcomes, clinical trials investigating new treatment paradigms are needed...
  28. doi request reprint Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, NC 27599, USA
    J Clin Oncol 26:2457-63. 2008
    ..To evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non-small-cell lung cancer (NSCLC)...
  29. ncbi request reprint Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431
    Everett E Vokes
    University of Chicago Medical Center and Cancer and Leukemia Group B, Chicago, IL, USA
    J Clin Oncol 20:4191-8. 2002
    ....
  30. ncbi request reprint Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)
    Rogerio C Lilenbaum
    The Mount Sinai Comprehensive Cancer Center, 4306 Alton Rd, Miami Beach, FL, USA
    J Clin Oncol 23:190-6. 2005
    ..We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer...
  31. ncbi request reprint Body surface area in dosing anticancer agents: scratch the surface!
    Antonius A Miller
    J Natl Cancer Inst 94:1822-3. 2002
  32. ncbi request reprint Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study
    Cheri E Klein
    Department of Biopharmaceutical Sciences, The University of Illinois at Chicago, 833 South Wood Street MC 865, Chicago, IL 60612, USA
    Cancer Chemother Pharmacol 57:199-206. 2006
    ..To evaluate medication adherence, pharmacokinetics and exposure versus response relationships in patients with myelodysplastic syndromes (MDS)...
  33. ncbi request reprint A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871
    Lionel D Lewis
    Sections of Clinical Pharmacology and Hematology Oncology, Department of Medicine, Dartmouth Medical School, The Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 13:3302-11. 2007
    ..We hypothesized that the pharmacokinetics and pharmacodynamics of docetaxel, an i.v. administered cytotoxic and substrate for CYP3A4, CYP3A5, and ABCB1, would differ between African-American and Caucasian patients...
  34. ncbi request reprint Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)
    Stuart M Lichtman
    University of Chicago, Chicago, USA
    J Clin Oncol 24:1846-51. 2006
    ..To prospectively evaluate the pharmacokinetics and toxicity profile of paclitaxel in relation to patient age in adults > or = 55 years old...
  35. ncbi request reprint 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808
    Jeffrey A Bogart
    Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Int J Radiat Oncol Biol Phys 59:460-8. 2004
    ..To prospectively evaluate the feasibility of delivering 70 Gy once-daily thoracic radiotherapy (TRT), concurrent with chemotherapy, in the treatment of limited-stage small-cell lung cancer (L-SCLC)...
  36. ncbi request reprint The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective
    Mark J Ratain
    University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 12:3612s-6s. 2006
    ..It is anticipated that the results of the current studies will contribute significantly to the goal of individualizing cancer treatment...